CD7 and T-cell non-Hodgkin lymphoma: In contrast, CD7 CAR-T therapy has demonstrated significant efficacy in relapsed/refractory (R/R) T-cell lymphoma, with manageable CRS (12), the ORR was 100% (10/10), 9 patients attained CR (9/10), and 1 Monomorphic epitheliotropic intestinal T-cell lymphoma patient achieved partial remission (PR) (1/10).